Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center

Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines was supported by Medicilon

2023-07-11
|
Page View:

13.jpgRadiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon. The A549 and H1299 cells in exponential growth phase were treated with a repeated IR dose of 2 Gy each at room temperature and then returned to the incubator. 

Reference:

Kan Wu, et al. Capilliposide C from Lysimachia capillipes Restores Radiosensitivity in Ionizing Radiation-Resistant Lung Cancer Cells Through Regulation of ERRFI1/EGFR/STAT3 Signaling Pathway. Front Oncol. 2021 Apr 1;11:644117. doi: 10.3389/fonc.2021.644117. 

Return
Relevant News
Researchers designed and synthesized a photocaged PI3K inhibitor 1, which could be readily activated by UV irradiation to release a highly potent PI3K inhibitor 2. ADME studies were conducted by Medicilon
2023-07-11
Aberrant activation of the PI3K pathway has been intensively targeted for cancer therapeutics for decades. In this work, researchers designed and synthesized a novel photocaged PI3K inhibitor 1, which could be readily activated by UV irradiation to release a highly potent PI3K inhibitor 2. ADME studies of compounds 1 and 2 were conducted by Medicilon. Medicilon's pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody.
Apatinib inhibits Paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway
2023-07-11
Overexpression of VEGFR2 can offset the rescue effect of Apatinib on Paclitaxel-induced drug resistance of MGC803 cells. Apatinib inhibits Paclitaxel resistance of MGC803 cells via the VEGFR2 signaling pathway. In this research, the VEGFR2 sequences were designed and then amplified by RT-PCR. The sequences were then ligated with a pcDNA3.0 plasmid to construct a recombinant pcDNA3.0-VEGFR2 vector (Medicilon).
Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells. The pharmacokinetic study of the selective PAK4 inhibitor was carried out by Medicilon
2023-07-11
The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.